Phanichyakarn P, Wong E C
Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Asian Pac J Allergy Immunol. 1988 Dec;6(2):111-5.
Twenty-six children with chronic bronchial asthma, 19 boys and 7 girls, aged between 6 and 16 years with duration of asthma ranging from 1-12 years, were studied by a control, oral prednisolone 5 mg twice a day and inhaled budesonide 200 micrograms twice daily, each for 3 weeks. The clinical efficacy assessed daily by day and night symptom scores of cough, wheeze, sleep disturbance, limitation of activity, symptomatic inhaled terbutaline usage, daily morning and afternoon Peak Expiratory Flow Rate (PEFR), and weekly PEFR and Forced Expiratory Volume in 1 second (FEV1) in percent of predict, showed statistically significant improvement during the inhaled budesonide aerosol and oral prednisolone treatment periods in comparison with the control. No side effect was observed during any study periods.
对26名患有慢性支气管哮喘的儿童进行了研究，其中19名男孩和7名女孩，年龄在6至16岁之间，哮喘病程为1至12年。研究采用对照方式，一组口服泼尼松龙5毫克，每日两次，另一组吸入布地奈德200微克，每日两次，每组治疗3周。通过每日评估咳嗽、喘息、睡眠障碍、活动受限、使用吸入性特布他林缓解症状的情况、每日早晚的呼气峰值流速（PEFR）以及每周的PEFR和第一秒用力呼气量（FEV1）占预计值的百分比等日夜症状评分来评估临床疗效。结果显示，与对照组相比，吸入布地奈德气雾剂和口服泼尼松龙治疗期间有统计学意义的显著改善。在任何研究期间均未观察到副作用。
